Mersana Therapeutics, Inc.
MRSNNASDAQHealthcare
$29.08
+$0.00(+0.00%)
Market Cap$145363650
P/E Ratio—
52W High$30.39
52W Low$5.21
Mersana Therapeutics, Inc. (MRSN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MRSN · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 2, 2026EPS Actual
-$2.75
Est. -$3.05 · +10.0%
Revenue
—
Est. $0.00B
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 2, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
MRSN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 2, 2026 | -$3.05 | -$2.75 | +10.0% | — | $0.00B | — |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$1.44 | -$1.51 | -4.9% | $0.01B | $0.00B | +442.3% |
| ▼ Q3 FY2025 | Aug 13, 2025 | -$3.75 | -$4.08 | -8.8% | $0.00B | $0.01B | -71.2% |
| ▲ Q2 FY2025 | May 15, 2025 | -$5.25 | -$4.75 | +9.5% | $0.00B | $0.01B | -55.0% |
| ▲ Q1 FY2025 | Mar 3, 2025 | -$0.16 | -$0.11 | +31.3% | $0.02B | $0.01B | +162.3% |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.18 | -$0.09 | +50.0% | $0.01B | $0.01B | +64.9% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -$0.18 | -$0.20 | -11.1% | $0.00B | $0.01B | -73.7% |
| ▲ Q2 FY2024 | May 9, 2024 | -$0.18 | -$0.16 | +11.1% | $0.01B | $0.01B | +8.7% |
Q1 FY2026
Mar 2, 2026Beat
EPS Actual
-$2.75
EPS Est.
-$3.05
EPS Surpr.
+10.0%
Revenue
—
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$1.51
EPS Est.
-$1.44
EPS Surpr.
-4.9%
Revenue
$0.01B
Q3 FY2025
Aug 13, 2025Miss
EPS Actual
-$4.08
EPS Est.
-$3.75
EPS Surpr.
-8.8%
Revenue
$0.00B
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$4.75
EPS Est.
-$5.25
EPS Surpr.
+9.5%
Revenue
$0.00B
Q1 FY2025
Mar 3, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$0.16
EPS Surpr.
+31.3%
Revenue
$0.02B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.09
EPS Est.
-$0.18
EPS Surpr.
+50.0%
Revenue
$0.01B
Q3 FY2024
Aug 13, 2024Miss
EPS Actual
-$0.20
EPS Est.
-$0.18
EPS Surpr.
-11.1%
Revenue
$0.00B
Q2 FY2024
May 9, 2024Beat
EPS Actual
-$0.16
EPS Est.
-$0.18
EPS Surpr.
+11.1%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-3.85 | $-3.85 | $-3.85 | 1 |
| Q3 FY2027 | $-3.88 | $-3.88 | $-3.88 | 1 |
| Q2 FY2027 | $-3.55 | $-3.55 | $-3.55 | 1 |
| Q1 FY2027 | $-3.58 | $-3.58 | $-3.58 | 1 |
| Q4 FY2026 | $-2.16 | $-2.16 | $-2.16 | 1 |
| Q3 FY2026 | $-2.33 | $-2.33 | $-2.33 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 2, 2026 | +10.0% | $29.08 | — | — |
| ▼ Q4 FY2025 | Nov 14, 2025 | -4.9% | $27.43 | $27.92 | +1.79% |
| ▼ Q3 FY2025 | Aug 13, 2025 | -8.8% | $6.07 | $6.81 | +12.19% |
| ▲ Q2 FY2025 | May 15, 2025 | +9.5% | $9.50 | $7.88 | -17.05% |
| ▲ Q1 FY2025 | Mar 3, 2025 | +31.3% | $13.07 | $12.00 | -8.19% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +50.0% | $55.00 | $65.75 | +19.55% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -11.1% | $35.50 | $33.75 | -4.93% |
| ▲ Q2 FY2024 | May 9, 2024 | +11.1% | $85.00 | $61.63 | -27.49% |
Q1 FY2026—
Report Date
Mar 2, 2026
EPS Beat/Miss
+10.0%
Price Before
$29.08
Price After
—
Q4 FY2025+1.79%
Report Date
Nov 14, 2025
EPS Beat/Miss
-4.9%
Price Before
$27.43
Price After
$27.92
Q3 FY2025+12.19%
Report Date
Aug 13, 2025
EPS Beat/Miss
-8.8%
Price Before
$6.07
Price After
$6.81
Q2 FY2025-17.05%
Report Date
May 15, 2025
EPS Beat/Miss
+9.5%
Price Before
$9.50
Price After
$7.88
Q1 FY2025-8.19%
Report Date
Mar 3, 2025
EPS Beat/Miss
+31.3%
Price Before
$13.07
Price After
$12.00
Q4 FY2024+19.55%
Report Date
Nov 13, 2024
EPS Beat/Miss
+50.0%
Price Before
$55.00
Price After
$65.75
Q3 FY2024-4.93%
Report Date
Aug 13, 2024
EPS Beat/Miss
-11.1%
Price Before
$35.50
Price After
$33.75
Q2 FY2024-27.49%
Report Date
May 9, 2024
EPS Beat/Miss
+11.1%
Price Before
$85.00
Price After
$61.63
Avg Beat Reaction-8.29%
Avg Miss Reaction+3.02%
Beat Rate5 / 8 quarters
Largest Move-27.49% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MRSN ends December
Mersana Therapeutics, Inc. (MRSN) most recently reported earnings on March 2, 2026 for Q1 FY2026, posting EPS of $-2.75 — beating the analyst consensus of $-3.05 by +10.0%. The next MRSN earnings date is expected around September 1, 2026.
Each quarter, investors track MRSN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MRSN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MRSN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MRSN earnings · 5 questionsMersana Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. MRSN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MRSN historically reports after market close (AMC).
MRSN earnings datewhen is MRSN earningsMRSN next earnings datewhen does MRSN report earningsMRSN earnings calendar
▸ Source: FMP · Mersana Therapeutics, Inc. SEC filings · US GAAP · Mersana Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026